Figure 1 from Repurposing Vandetanib plus Everolimus for the Treatment of &lt;i&gt;ACVR1&lt;/i&gt;-Mutant Diffuse Intrinsic Pontine Glioma

Diana Carvalho; Peter J. Richardson; Nagore G. Olaciregui; Reda Stankunaite; Cinzia Lavarino; Valeria Molinari; Elizabeth A. Corley; Daniel P. Smith; Ruth Ruddle; Adam Donovan; Ákos Pál; Florence I. Raynaud; Sara Temelso; Alan Mackay; John P. Overington; Anne M. Phelan; David N. Sheppard; Andrew Mackinnon; Bassel Zebian; Safa Al‐Sarraj; Ashirwad Merve; Jeremy Pryce; Jacques Grill; Michael Hubank; Ofelia Cruz; Andrés Morales La Madrid; Sabine Mueller; Ángel M. Carcaboso; Fernando Carceller; Chris Jones

doi:10.1158/2159-8290.30834247

Abstract

Schema for AI-based identification of a repurposed drug combination strategy for ACVR1-mutant DIPG. The BenevolentAI knowledge graph was employed to identify approved drugs with potential potency against ACVR1 and sufficient CNS penetration to be a rational therapy for children with DIPG. Vandetanib and everolimus were validated to inhibit ACVR1 and P-gp, respectively, and the combination was found to be synergistic in vitro and prolong survival in vivo, leading to the clinical use of this combination in four expert pediatric neuro-oncology centers in Europe. ctDNA, circulating tumor DNA.

Related Publications

A National Registry to Determine the Distribution and Prevalence of Parkinson’s Disease in Thailand: Implications of Urbanization and Pesticides as Risk Factors for Parkinson’s Disease

Roongroj Bhidayasiri , Natnipa Wannachai , Sudaratana Limpabandhu +9 more

Background: Parkinson’s disease (PD) occurs worldwide but prior to this review of data from the Thailand Parkinson’s Disease Registry there had been no nation...

2011 Neuroepidemiology 50 citations

Factors Associated With Ischemic Stroke During Aspirin Therapy in Atrial Fibrillation

Robert G. Hart , Lesly A. Pearce , Ruth McBride +2 more

Background and Purpose —Nonvalvular atrial fibrillation (AF) is a strong, independent risk factor for stroke, but the absolute rate of stroke varies widely among AF patients, im...

1999 Stroke 533 citations

Publication Info

Year: 2025
Type: article
Citations: 0
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Figure 1 from Repurposing Vandetanib plus Everolimus for the Treatment of ACVR1-Mutant Diffuse Intrinsic Pontine Glioma

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

OpenAlex

Cite This

APA Style

                            
                                    Diana Carvalho, 
                                
                                    Peter J. Richardson, 
                                
                                    Nagore G. Olaciregui
                                
                                et al.
                            
                            (2025). 
                            Figure 1 from Repurposing Vandetanib plus Everolimus for the Treatment of &lt;i&gt;ACVR1&lt;/i&gt;-Mutant Diffuse Intrinsic Pontine Glioma. 
                            
                            .
                            https://doi.org/10.1158/2159-8290.30834247

Identifiers

DOI: 10.1158/2159-8290.30834247